The pharmaceutical sector continues to rally, with innovation and international expansion serving as key drivers.

Release time：

2023-03-02

This week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming the CSI 300 Index by 0.87 percentage points, with year-to-date gains reaching 3.93%. Sub-sectors such as pharmaceutical R&D outsourcing, hospitals, and medical equipment delivered particularly strong performance.

 　　This week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming the CSI 300 Index by 0.87 percentage points, with year-to-date gains reaching 3.93%. Sub-sectors such as pharmaceutical R&D outsourcing, hospitals, and medical devices delivered particularly strong performance. On the policy front, the “Implementation Plan for End-to-End Support of Innovative Drug Development” is being steadily rolled out, with a success rate exceeding 90% in national medical insurance negotiations, and continuous improvements in pricing, reimbursement, and hospital access procedures for innovative drugs. Meanwhile, the National Healthcare Security Administration is encouraging commercial health insurers to participate in the reimbursement of innovative drugs, further refining the diversified payment system. Taking BeiGene as an example, its core product, zanubrutinib, recorded global sales of over RMB 8 billion in the first three quarters of 2024, with more than 80% of sales coming from European and U.S. markets, and its A-share market capitalization has now surpassed that of Hengrui Medicine. Driven by the dual pillars of “innovation-driven growth” and “going global,” domestically developed innovative drugs are steadily enhancing their global competitiveness and are poised to capture a larger share of the international market in the future. 